Donald School Journal of Ultrasound in Obstetrics and Gynecology

Register      Login

VOLUME 12 , ISSUE 2 ( April-June, 2018 ) > List of Articles

EDITORIAL

1989–2019: 30 Years of 3D Ultrasound in Obstetrics and Gynecology

Eberhard Merz

Keywords : Four-dimensional ultrasound, HDlive mode, Silhouette mode, Three-dimensional ultrasound

Citation Information : Merz E. 1989–2019: 30 Years of 3D Ultrasound in Obstetrics and Gynecology. Donald School J Ultrasound Obstet Gynecol 2018; 12 (2):94-98.

DOI: 10.5005/jp-journals-10009-1557

License: CC BY-NC 4.0

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Three-dimensional (3D)/four-dimensional (4D) ultrasound has profited greatly from the developments in computer and 3D probe technology. It has become such a sophisticated technique in the fields of prenatal diagnosis, gynecology, and breast diagnosis that it is indispensable for the skilled ultrasound operator. It represents a problem-solving tool in different circumstances, not only in the demonstration of pathological findings, but also in the verification of normal findings. This is particularly important in obstetrics in patients with an increased risk for a specific fetal malformation. In such a situation, the parents-to-be can easily be reassured by being shown the normal fetal anatomy. On the contrary, with the ability to demonstrate the fetus to the parents-to-be as in a photograph, there may be a risk that they believe 3D ultrasound to be able to detect any possible defect and can thus guarantee the “perfect baby.” However, this would definitively be the wrong conclusion.


PDF Share
  1. Szilard J. An improved three-dimensional display system. Ultrasonics 1974 Nov;12(6):273-276.
  2. Kirbach D, Whittingham TA. 3D ultrasound—the Kretztechnik Voluson® approach. Eur J Ultrasound 1994;1:85-89.
  3. Merz E. 25 years of 3D ultrasound in prenatal diagnosis (1989- 2014). Ultraschall Med 2015 Feb;36(1):2-8.
  4. Merz E. 3-D ultrasound in prenatal diagnosis. In: Merz E, ed. Ultrasound in obstetrics and gynecology. Vol. 1: Obstetrics. New York: Thieme Stuttgart; 2005. pp. 516-528.
  5. Merz E. Current 3D/4D ultrasound technology in prenatal diagnosis. Eur Clin Obstet Gynaecol 2005;1:184-193.
  6. Merz E, Abramowicz JS. 3D/4D ultrasound in prenatal diagnosis: is it time for routine use? Clin Obstet Gynecol 2012 Mar;55(1):336-351.
  7. Merz E, Weber G, Bahlmann F, Miric-Tesanic D. Application of transvaginal and abdominal three-dimensional ultrasound for the detection or exclusion of malformations of the fetal face. Ultrasound Obstet Gynecol 1997 Apr;9(4):237-243.
  8. Baba K, Okai T, Kozuma S, Taketani Y. Fetal abnormalities: evaluation with real-time-processible three-dimensional US—preliminary report. Radiology 1999 May;211(2):441-446.
  9. Timor-Tritsch IE, Monteagudo A, Mayberry P. Threedimensional ultrasound evaluation of the fetal brain: the three horn view. Ultrasound Obstet Gynecol 2000 Sep;16(4): 302-306.
  10. Rotten D, Levaillant JM. Two-and three-dimensional sonographic assessment of the fetal face. 2. Analysis of cleft lip, alveolus and palate. Ultrasound Obstet Gynecol 2004 Sep;24(4):402-411.
  11. Benacerraf BR, Benson CB, Abuhamad AZ, Copel JA, Abramowicz JS, Devore GR, Doubilet PM, Lee W, Lev-Toaff AS, Merz E, et al. Three- and 4-dimensional ultrasound in obstetrics and gynecology: proceedings of the American Institute of Ultrasound in Medicine Consensus Conference. J Ultrasound Med 2005 Dec;24(12):1587-1597.
  12. Merz E, Welter C. 2D and 3D ultrasound evaluation of normal and abnormal fetal anatomy in the second and third trimesters in a level III center. Ultraschall Med 2005 Feb;26(1):9-16.
  13. Benoit B, Chaoui R. Three-dimensional ultrasound with maximal mode rendering: a novel technique for the diagnosis of bilateral or unilateral absence or hypoplasia of nasal bones in second-trimester screening for Down syndrome. Ultrasound Obstet Gynecol 2005 Jan;25(1):19-24.
  14. Merz E, Benoit B, Blass HG, Baba K, Kratochwil A, Nelson T, Pretorius D, Jurkovic D, Chang FM, Lee A. Standardization of three-dimensional images in obstetrics and gynecology: consensus statement. Ultrasound Obstet Gynecol 2007 Jun;29(6):697-703.
  15. Merz E, Abramovicz J, Baba K, Blaas HG, Deng J, Gindes L, Lee W, Platt L, Pretorius D, Schild R, et al. 3D imaging of the fetal face—recommendations from the International 3D Focus Group. Ultraschall Med 2012 Apr;33(2):175-182.
  16. Andresen C, Matias A, Merz E. Fetal face: the whole picture. Ultraschall Med 2012 Oct;33(5): 431-440.
  17. El Guindi W, Dreyfus M, Carles G, Lambert V, Herlicoviez M, Benoist G. 3D ultrasound and Doppler angiography for evaluation of fetal cardiovascular anomalies. Int J Gynaecol Obstet 2013 Feb;120(2):173-177.
  18. Pashaj S, Merz E, Wellek S. Biometric measurements of the fetal corpus callosum by three-dimensional ultrasound. Ultrasound Obstet Gynecol 2013 Dec;42(6):691-698.
  19. Bonilla-Musoles F, Raga F, Osborne NG, Bonilla F Jr, Caballero O, Climent MT, Wallraf SH, Castillo JC. Multimodality 3-dimensional volumetric ultrasound in obstetrics and gynecology with an emphasis in HDlive technique. Ultrasound Q 2013 Sep;29(3):189-201.
  20. Pashaj S, Merz E. Prenatal demonstration of normal variants of the pericallosal artery by 3D ultrasound. Ultraschall Med 2014 Apr;35(2):129-136.
  21. Tonni G, Grisolia G, Sepulveda W. Second trimester fetal neurosonography: reconstructing cerebral midline anatomy and anomalies using a novel three-dimensional ultrasound technique. Prenat Diagn 2014 Jan;34(1):75-83.
  22. Leibovitz Z, Haratz KK, Malinger G, Shapiro I, Pressman C. Fetal posterior fossa dimensions: normal and anomalous development assessed in mid-sagittal cranial plane by three-dimensional multiplanar sonography. Ultrasound Obstet Gynecol 2014 Feb;43(2):147-153.
  23. Pashaj S, Merz E. Detection of fetal corpus callosum abnormalities by means of 3D ultrasound. Ultraschall Med 2016 Apr;37(2):185-194.
  24. Tutschek B, Blaas HK, Abramowicz J, Baba K, Deng J, Lee W, Merz E, Platt L, Pretorius D, Timor-Tritsch IE, et al. Threedimensional ultrasound imaging of the fetal skull and face. Ultrasound Obstet Gynecol 2017 Jul;50(1):7-16.
  25. Merz E, Pashaj S. Advantages of 3D ultrasound in the assessment of fetal abnormalities. J Perinat Med 2017 Aug 28;45(6):643-650.
  26. Merz E, Pashaj S. True or false umbilical cord knot? Differentiation via 3D/4D color Doppler ultrasound. Ultraschall Med 2018 Apr;39(2):127-128.
  27. Pooh RK, Kurjak A. Novel application of three-dimensional HDlive imaging in prenatal diagnosis from the first trimester. J Perinat Med 2015 Mar;43(2):147-158.
  28. Pooh RK. “See-through fashion” in prenatal diagnostic imaging. Donald School J Ultrasound Obstet Gynecol 2015;9:111.
  29. Merz E. Physiological umbilical herniation—a distinctive sonographic feature in the embryonic stage. Ultraschall Med 2017 Apr;38(2):123-124.
  30. Kurjak A, Barisic LS, Stanojevic M, Porovic S. Are we ready to investigate cognitive function of fetal brain? The role of advanced four-dimensional sonography. Donald School J Ultrasound Obstet Gynecol 2016 Jan;10(2):116-124.
  31. Salihagiæ-Kadiæ A, Kurjak A. Cognitive function of the fetus. Ultraschall Med 2018 Apr;39(2):181-189.
  32. Stanojevic M, Kurjak A, Salihagiæ-Kadiæ A, Vasilj O, Miskovic B, Shaddad AN, Ahmed B, Tomasoviæ S. Neurobehavioral continuity from fetus to neonate. J Perinat Med 2011 Mar;39(2): 171-177.
  33. Kurjak A, Miskovic B, Stanojevic M, Amiel-Tison C, Ahmed B, Azumendi G, Andonotopo W, Turudic T, Salihagiæ-Kadiæ A. New scoring system for fetal neurobehaviour assessed by three- and four-dimensional sonography. J Perinat Med 2008;36(1):73-81.
  34. Kurjak A, Antsaklis P, Stanojevic M, Vladareanu R, Vladareanu S, Neto RM, Barisic LS, Porovic S, Delic T. Multicentric studies of the fetal neurobehavior by KANET test. J Perinat Med 2017 Aug;45(6):717-727.
  35. Devore GR, Falkensammer P, Sklansky MS, Platt LD. Spatiotemporal image correlation (STIC): new technology for evaluation of the fetal heart. Ultrasound Obstet Gynecol 2003 Oct;22(4):380-387.
  36. Chaoui R, Heling KS. New developments in fetal heart scanning: three-and four-dimensional fetal echocardiography. Semin Fetal Neonatal Med 2005 Dec;10(6):567-577.
  37. Hata T, AboEllail MA, Sajapala S, Ishimura M, Masaoka H. HDlive Silhouette mode with spatiotemporal image correlation for assessment of the fetal heart. J Ultrasound Med 2016 Jul;35(7):1489-1495.
  38. DeVore GR, Satou G, Sklansky M. 4D fetal echocardiography— an update. Echocardiography 2017 Dec;34(12):1788-1798.
  39. Tedesco GD, de Souza Bezerra M, Barros FS, Martins WP, Nardozza LM, Carrilho MC, Moron AF, Carvalho FH, Rolo LC, Araujo Júnior E. Reference ranges of fetal cardiac biometric parameters using three-dimensional ultrasound with spatiotemporal image correlation M mode and their applicability in congenital heart diseases. Pediatr Cardiol 2017 Feb;38(2):271-279.
  40. Guasina F, Bellussi F, Morganelli G, Salsi G, Pilu G, Simonazzi G. Electronic spatiotemporal image correlation improves fourdimensional fetal echocardiography. Ultrasound Obstet Gynecol 2018 Mar;51(3):357-360.
  41. Merz E, Pashaj S. Current role of 3D/4D sonography in obstetrics and gynecology. Donald School J Ultrasound Obstet Gynecol 2013;7(4):400-408.
  42. Merz E. Transvaginal 3D/4D ultrasound and its application in gynecology. In: Merz E, ed. Ultrasound in obstetrics and gynecology. Vol. 2: Gynecology. New York, Stuttgart: Thieme;2007. pp. 222-240.
  43. Dietz HP. Ultrasound imaging of the pelvic floor. Part II: threedimensional or volume imaging. Ultrasound Obstet Gynecol 2004 Jun;23(6):615-625.
  44. Dietz HP, Moegni F, Shek KL. Diagnosis of levator avulsion injury: a comparison of three methods. Ultrasound Obstet Gynecol 2012;40:693-698.
  45. Moini A, Mohammadi S, Hosseini R, Eslami B, Ahmadi F. Accuracy of 3-dimensional sonography for diagnosis and classification of congenital uterine anomalies. J Ultrasound Med 2013 Jun;32(6):923-927.
  46. Tabi S, Kupesic Plavsic S. The role of three-dimensional ultrasound in the assessment of congenital uterine anomalies. Donald School J Ultrasound Obstet Gynecol 2012;6(4): 415-423.
  47. Jurkovic D, Geipel A, Gruboeck K, Jauniaux E, Natucci M, Campbell S. Three-dimensional ultrasound for the assessment of uterine anatomy and detection of congenital anomalies: a comparison with hysterosalpingography and two-dimensional sonography. Ultrasound Obstet Gynecol 1995 Apr;5(4):233-237.
  48. Mercé LT, Barco MJ, Bau S, Troyano JM. Prediction of ovarian response and IVF/ICSI outcome by three-dimensional ultrasonography and power Doppler angiography. Eur J Obstet Gynecol Reprod Biol 2007 May;132(1):93-100.
  49. Zhang T, He Y, Wang Y, Zhu Q, Yang J, Zhao X, Sun Y. The role of three-dimensional power Doppler ultrasound parameters measured on hCG day in the prediction of pregnancy during in vitro fertilization treatment. Eur J Obstet Gynecol Reprod Biol 2016 Aug;203:66-71.
  50. Maged AM, Ramzy AM, Ghar MA, El Shenoufy H, Gad Allah SH, Wahba AH, ElKateb AY, Hwedi N. 3D ultrasound assessment of endometrial junctional zone anatomy as a predictor of the outcome of ICSI cycles. Eur J Obstet Gynecol Reprod Biol 2017 May;212:160-165.
  51. Raine-Fenning N, Jayaprakasan K, Clewes J, Joergner I, Bonaki SD, Chamberlain S, Devlin L, Priddle H, Johnson I. SonoAVC: a novel method of automatic volume calculation. Ultrasound Obstet Gynecol 2008 Jun;31(6):691-696.
  52. Zhou L, Zhang X, Chen X, Liao L, Pan R, Zhou N, Di N. Value of three-dimensional hysterosalpingo-contrast sonography with SonoVue in the assessment of tubal patency. Ultrasound Obstet Gynecol 2012 Jul;40(1):93-98.
  53. Exacoustos C, Di Giovanni A, Szabolcs B, Romeo V, Romanini ME, Luciano D, Zupi E, Arduini D. Automated three-dimensional coded contrast imaging hysterosalpingocontrast sonography: feasibility in office tubal patency testing. Ultrasound Obstet Gynecol 2013 Mar;41(3):328-335.
  54. Bonilla-Musoles F, Raga F, Osborne NG, Blanes J. Control of intrauterine device insertion with three-dimensional ultrasound: is it the future? J Clin Ultrasound 1996 Jun;24(5): 263-267.
  55. Benacerraf BR, Shipp TD, Bromley B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are a source of pelvic pain and abnormal bleeding. Ultrasound Obstet Gynecol 2009 Jul;34(1): 110-115.
  56. Chou CY, Hsu KF, Wang ST, Huang SC, Tzeng CC, Huang KE. Accuracy of three-dimensional ultrasonography in volume estimation of cervical carcinoma. Gynecol Oncol 1997 Jul;66(1): 89-93.
  57. Alcazar JL, Jurado M. Three-dimensional ultrasound for assessing women with gynecological cancer: a systematic review. Gynecol Oncol 2011 Mar;120(3):340-346.
  58. Pascual MA, Graupera B, Hereter L, Rotili A, Rodriguez I, Alcazar JL. Intra- and interobserver variability of 2D and 3D transvaginal sonography in the diagnosis of benign versus malignant adnexal masses. J Clin Ultrasound 2011 Jul;39(6):316-321.
  59. Acharya UR, Sree SV, Krishnan MM, Saba L, Molinari F, Guerriero S, Suri JS. Ovarian tumor characterization using 3D ultrasound. Technol Cancer Res Treat 2012 Dec;11(6):543-552.
  60. Belitsos P, Papoutsis D, Rodolakis A, Mesogitis S, Antsaklis A. Three-dimensional power Doppler ultrasound for the study of cervical cancer and precancerous lesions. Ultrasound Obstet Gynecol 2012 Nov;40(5):576-581.
  61. Perez-Medina T, Orensanz I, Pereira A, Valero de Bernabé J, Engels V, Troyano J, SanFrutos L, Iglesias E. Three-dimensional angioultrasonography for the prediction of malignancy in ovarian masses. Gynecol Obstet Invest 2013;75(2):120-125.
  62. Rotten D, Levaillant JM, Zerat L. Analysis of normal breast tissue and of solid breast masse using three-dimensional ultrasound mammography. Ultrasound Obstet Gynecol 1999 Aug;14(2):114-124.
  63. Merz E, Oberstein A. 3D and 4D breast ultrasound. In: Ultrasound in obstetrics and gynecology. Vol. 2: Gynecology. New York: Thieme Stuttgart; 2007. pp. 266-296.
  64. Weismann C, Mayr C, Egger H, Auer A. Breast sonography— 2D, 3D, 4D ultrasound or elastography? Breast Care 2011;6:98-103.
  65. Vourtsis A, Kachulis A. The performance of 3D ABUS versus HHUS in the visualisation and BI-RADS characterisation of breast lesions in a large cohort of 1,886 women. Eur Radiol 2018 Feb;28(2):592-601.
  66. Meel-van den Abeelen AS, Weijers G, van Zelst JC, Thijssen JM, Mann RM, de Korte CL. 3D quantitative breast ultrasound analysis for differentiating fibroadenomas and carcinomas smaller than 1 cm. Eur J Radiol 2017 Mar;88:141-147.
  67. Weismann CF, Forstner R, Prokop E, Rettenbacher T. Threedimensional targeting: a new three-dimensional ultrasound technique to evaluate needle position during breast biopsy. Ultrasound Obstet Gynecol 2000 Sep;16(4):359-364.
  68. Delle Chiaie L, Terinde R. Three-dimensional ultrasoundvalidated large-core needle biopsy: is it a reliable method for the histological assessment of breast lesions? Ultrasound Obstet Gynecol 2004 Apr;23(4):393-397.
  69. Kurjak A. 3D/4D sonography (Editorial). J Perinat Med 2017 Aug 28;45(6):639-641.
  70. Islam MS, Protic O, Giannubilo SR, Toti P, Tranquilli AL, Petraglia F, Castellucci M, Ciarmela P. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013 Mar;98(3):921-934.
  71. Ciarmela P, Ciavattini A, Giannubilo SR, Lamana P, Fiorini R, Tranquili AL, Christman GM, Castellucciu M. Management of leiomyomas in perimenopausal women. Maturitas 2014 Jul; 78(3):168-173.
  72. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005;59(1):29-35.
  73. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991 May;77(5):720-725.
  74. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006 Dec;108(6):1381-1387.
  75. Carbonell Esteve JL, Acosta R, Heredia B, Perez Y, Castaneda MC, Hernandez AV. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008 Nov;112(5):1029-1036.
  76. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012 Feb;366(5): 409-420.
  77. Ghezzi F, Cromi A, Bergamini V, Scarperi S, Bolis P, Franchi M. Midterm outcome of radiofrequency thermal ablation for symptomatic uterine myomas. Surg Endosc 2007 Nov;21(11): 2081-2085.
  78. Kanaoka Y, Yoshida C, Fukuda T, Kajitani K, Ishiko O. Transcervical microwave myolysis for uterine myomas assisted by transvaginal ultrasonic guidance. J Obstet Gynaecol Res 2009 Feb;35(1):145-151.
  79. Stewart EA, Rabinovici J, Tempany CM, Inbar Y, Regan L, Gostout B, Hesley G, Kim HS, Hengst S, Gedroyc WM. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006 Jan;85(1):22-29.
  80. Taran FA, Tempany CM, Regan L, Inbar Y, Revel A, Stewart EA. Magnetic resonance-guided focused ultrasound (MRgFUS) compared with abdominal hysterectomy for treatment of uterine leiomyomas. Ultrasound Obstet Gynecol 2009 Nov;34(5):572-578.
  81. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990.1997. Obstet Gynecol 2002 Feb;99(2):229-234.
  82. Cicinelli E, Romano F, Anastasio PS, Blasi N, Parisi C, Galantino P. Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas. Obstet Gynecol 1995 Jan; 85(1):42-47.
  83. Furr BJA, Jordan VC. The pharmacology and clinical uses of Tamoxifen. Pharmacol Ther 1984;25(2):127-205.
  84. Barakat R. The effect of Tamoxifen on the endometrium. Oncology 1995 Feb;9(2):129-142.
  85. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994 Sep;47(9):827-833.
  86. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Tamoxifen and the uterus and endometrium. Lancet 1989 Feb; 1(8634):375.
  87. Kedar RP, Bourne TH, Powels TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994 May;343(8909):1318-1321.
  88. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomized control trial. Gynecol Oncol 2009 Sep;114(3):452-456.
  89. Deligdisch L, Kalir T, Cohen CJ, de Latour M, le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000 Aug;78(2):181-186.
  90. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004 Aug;94(2):256.
  91. Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol 2011 Dec;205(6):535.e1-5.
  92. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994 Apr;86(7):527-537.
  93. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994 Feb;343(8895):448-452.
  94. Deligdisch L, Kalir N, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000 Aug;78(2):181-186.
  95. Ryden S, Fermo M, Moller T. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 1992;31(2):271-274.
  96. Cummings FJ, Gray R, Tormey DC, Davis TE, Volk H, Harris J, Falkson G, Bennett JM. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993;11(1):29-35.
  97. Fotiou S, Hatjeleftheriou G, Kyrousis G, Kokka F, Apostolikas N. Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature. Anticancer Res 2000 May;20(3B):2015-2020.
  98. Cohen R, Perel E, Flex E, Tepper R, Altaras MM, Cordoba M, Beyth Y. Endometrial pathologies in postmenopausal tamoxifen treatment: comparison between gynaecological symptomatic and gynaecological asymptomatic breast cancer patients. J Clin Pathol 1999 Apr;52(4):278-282.
  99. Cohen R, Azaria, J. Shapira, Yigael D, Tepper R. The significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer 2002 Jun;94(12):3101-3106.
  100. El.bieta S, Tomasz K, Jacek J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004 May;30(3):291-301.
  101. Tamoxifen and uterine cancer. Committee Opinion No 601. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:1394-1397.
  102. Gerber B, Krause A, Muller H, Reimer T, Külz T, Makovitzky J, Kundt G, Friese K. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000 Oct;18(20):3464-3470.
  103. Markovitch O, Tepper R, Aviram R, Fishman A, Shapira J, Cohen I. The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 2004 Sep;94(3):754-759.
  104. Berliere M, Radikov G, Galant C, Piette P, Marbaix E, Donnez J. Identification of women at high risk of developing endometrial cancer on tamoxifen. Eur J Cancer 2000 Sep;36(suppl 4): S35-S36.
  105. Vosse M, Renard F, Coibion M, Neven P, Nogaret JM, Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 2002 Feb;101(1):58-63.
  106. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005 Apr;192(4):1230-1237.
  107. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel releasingintrauterine system for endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol 2010 Dec;203(6):547.e1-547.e10.
  108. Chan SS, Tam WH, Yeo W, Yu MMY, Ng DPS, Wong AWY, Kwan WH, Yuen PM. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007 Dec;114(12):1510-1515.
  109. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel-releasing intrauterinesystem; long-term follow-up of a randomised control trial. Gynecol Oncol 2009 Sep;114(3):452-456.
  110. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011 Mar;83(3):211-217.
  111. Stein RI, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-185.
  112. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 Jan;97(1):28-38.e25
  113. Sirmans SM, Pate KA. Epidemiology, diagnosis and management of polycystic ovary syndrome. Clin Epidemiol 2014; 6:1-13.
  114. Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, Hamamah S, Simón C, Devroey P, Ezcurra D, et al. Contemporary genetic technologies and female reproduction. Human Reproduction Update 2011 Nov;17(6):829-847.
  115. Balen A, Conway G, Kaltsas G. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995 Aug;10(8):2107-2111.
  116. Azziz R, Sanchez L, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004 Feb;89(2):453-462.
  117. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000 May;52(5):595-600.
  118. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007 Jun;87(6): 1369-1376.
  119. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Givens JHF, Merriman G, editors. The polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 1992. p. 377-384.
  120. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19-25.
  121. Azziz R, Carmina E, DeWailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006 Nov;91(11):4237-4245.
  122. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, Haider E, Pierson RA, Chizen DR. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013 May;28(5):1361-1368.
  123. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011 Feb;3:25-35.
  124. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No 108: Polycystic ovary syndrome. Obstet Gynecol 2009 Oct;114(4):936-949.
  125. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008 Mar;89(3): 505-522.
  126. Balen AH. Ovulation induction in the management of anovulatory polycystic ovary syndrome. Mol Cell Endocrinol 2013 Jul;373(1-2):77-82.
  127. Berridge DL, Winter TC. Saline infusion sonohysterography: technique, indications, and imaging findings. J Ultrasound Med 2004 Jan;23(1):97-112.
  128. Allison SJ, Horrow MM, Kim HY, Lev-Toaff AS. Salineinfused sonohysterography: tips for achieving greater success. Radiographics 2011 Nov-Dec;31(7):1991-2004.
  129. O'Neill MJ. Sonohysterography. Radiol Clin North Am 2003 Jul;41(4):781-797.
  130. Bonnamy L, Marret H, Perrotin F, Body G, Berger C, Lansac J. Sonohysterography: a prospective survey of results and complications in 81 patients. Eur J Obstet Gynecol Reprod Biol 2002 Apr;102(1):42-47.
  131. Lindheim SR, Adsuar N, Kushner DM, Pritts EA, Olive DL. Sonohysterography: a valuable tool in evaluating the female pelvis. Obstet Gynecol Surv 2003 Nov;58(11):770-784.
  132. Lindheim SR, Sprague C, Winter TC. Hysterosalpingography and sonohysterography: lessons in technique. AJR Am J Roentgenol 2006 Jan;186(1):24-29.
  133. Jeanty P, Besnard S, Arnold A, Turner C, Crum P. Air-contrast sonohysterography as a first step assessment of tubal patency. J Ultrasound Med 2000 Aug;19(8):519-527.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.